quinoxalines has been researched along with Coronary Restenosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arner, A; de Sá, VP; Ekblad, E; Harnek, J; Stenram, U; Zoucas, E | 1 |
| Amin, D; Bilder, G; Galczenski, H; He, W; Leadley, R; Luo, Y; McVey, M; Morgan, L; Myers, M; Natajaran, C; Needle, S; Perrone, M; Spada, A | 1 |
| Amin, D; Bilder, G; Galzcinski, H; Hanney, B; He, W; Maguire, MP; Myers, MR; Needle, S; Setzer, N; Spada, AP; Zulli, A | 1 |
3 other study(ies) available for quinoxalines and Coronary Restenosis
| Article | Year |
|---|---|
Intimal hyperplasia in balloon dilated coronary arteries is reduced by local delivery of the NO donor, SIN-1 via a cGMP-dependent pathway.
Topics: Actins; Analysis of Variance; Angioplasty, Balloon, Coronary; Animals; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Cyclic GMP; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Guanylate Cyclase; Hyperplasia; Intermediate Filaments; Molsidomine; Myosins; NAD(P)H Dehydrogenase (Quinone); NADP; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Oxadiazoles; Quinoxalines; Signal Transduction; Sus scrofa; Time Factors; Tunica Intima | 2011 |
Stent-induced restenosis in the swine coronary artery is inhibited by a platelet-derived growth factor receptor tyrosine kinase inhibitor, TKI963.
Topics: Administration, Oral; Animals; Cell Division; Cells, Cultured; Chemotaxis; Collagen; Coronary Restenosis; Coronary Vessels; Male; Mice; Muscle, Smooth, Vascular; Phosphorylation; Quinoxalines; Rats; Receptors, Platelet-Derived Growth Factor; Stents; Swine, Miniature | 2003 |
Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR exploration and effective bioisosteric replacement of a phenyl substituent.
Topics: Angioplasty, Balloon, Coronary; Aorta; Cell Division; Coronary Restenosis; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Muscle, Smooth, Vascular; Phosphorylation; Protein-Tyrosine Kinases; Quinoxalines; Receptors, Platelet-Derived Growth Factor; Structure-Activity Relationship | 2003 |